SAB Biotherapeutics, Inc. Annual Operating Lease, Payments in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
SAB Biotherapeutics, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2020 to 2023.
  • SAB Biotherapeutics, Inc. Operating Lease, Payments for the quarter ending September 30, 2024 was $195K, a 65.3% increase year-over-year.
  • SAB Biotherapeutics, Inc. Operating Lease, Payments for the twelve months ending September 30, 2024 was $918K, a 46.9% increase year-over-year.
  • SAB Biotherapeutics, Inc. annual Operating Lease, Payments for 2023 was $600K, a 50% decline from 2022.
  • SAB Biotherapeutics, Inc. annual Operating Lease, Payments for 2022 was $1.2M, a 4.62% increase from 2021.
  • SAB Biotherapeutics, Inc. annual Operating Lease, Payments for 2021 was $1.15M, a 103% increase from 2020.
Operating Lease, Payments, Trailing 12 Months (USD)
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $600K -$600K -50% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 $1.2M +$53K +4.62% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 $1.15M +$583K +103% Jan 1, 2021 Dec 31, 2021 10-K/A 2023-04-28
2020 $564K Jan 1, 2020 Dec 31, 2020 10-K/A 2023-04-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.